Activin signaling is an essential component of the TGF-β induced pro-metastatic phenotype in colorectal cancer

Loss of TGFβ signaling promotes colon cancer progression and tumor-associated inflammation

(2016) Daniel R. Principe et al.   Oncotarget

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer

(2015) Jessica Bauer et al.   Molecular Cancer

Translational regulation of inhibin βA by TGFβ via the RNA-binding protein hnRNP E1 enhances the invasiveness of epithelial-to-mesenchymal transitioned cells

(2015) B V Howley et al.   ONCOGENE

Targeting the TGFβ pathway for cancer therapy

(2015) Cindy Neuzillet et al.   PHARMACOLOGY & THERAPEUTICS

Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies

(2015) Haralambos Raftopoulos et al.   SUPPORTIVE CARE IN CANCER

Effect of 3 to 5 Years of Scheduled CEA and CT Follow-up to Detect Recurrence of Colorectal Cancer

(2014) John N. Primrose et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

TGF- : Duality of Function Between Tumor Prevention and Carcinogenesis

(2014) D. R. Principe et al.   JNCI-Journal of the National Cancer Institute

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations

(2013) Dmitri Mouradov et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Elevated expression of activins promotes muscle wasting and cachexia

(2013) Justin L. Chen et al.   FASEB JOURNAL

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer

(2013) Long Zhang et al.   TRENDS IN BIOCHEMICAL SCIENCES

Dependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation

(2012) Alexandre Calon et al.   CANCER CELL

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Targeting the TGFβ signalling pathway in disease

(2012) Rosemary J. Akhurst et al.   NATURE REVIEWS DRUG DISCOVERY

Effects of Activin and TGFβ on p21 in Colon Cancer

(2012) Jessica Bauer et al.   PLoS One

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

The TGFbeta Superfamily Signaling Pathway

(2012) Alexander Weiss et al.   Wiley Interdisciplinary Reviews-Developmental Biology

BARD1 Expression Predicts Outcome in Colon Cancer

(2011) Judith C. Sporn et al.   CLINICAL CANCER RESEARCH

A systematic review of treatment guidelines for metastatic colorectal cancer

(2011) M. S. Edwards et al.   Colorectal Disease

Partners in crime: the TGFβ and MAPK pathways in cancer progression

(2011) Douglas A Chapnick et al.   Cell and Bioscience

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

(2010) Stephen B. Edge et al.   ANNALS OF SURGICAL ONCOLOGY

Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival

(2010) Xiaolan Zhou et al.   CELL

Differential Regulation of Transforming Growth Factor β Signaling Pathways by Notch in Human Endothelial Cells

(2009) YangXin Fu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phospho-control of TGF-β superfamily signaling

(2008) Katharine H Wrighton et al.   CELL RESEARCH

LY2109761, a novel transforming growth factor   receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis

(2008) D. Melisi et al.   MOLECULAR CANCER THERAPEUTICS